The Leeds Teaching Hospitals NHS Trust

New facility puts LTHT at forefront of Cardiovascular research

16 December 2014

The new Cardiovascular Clinical Research Facility (CV-CRF) in the Jubilee Wing at Leeds General Infirmary has been officially opened by Mr Edward Ziff, Chair of the Leeds Teaching Hospitals Charitable Foundation.

The Foundation, which is the charitable arm of the Leeds Teaching Hospitals, has provided funding of £250,000 in staff and infrastructure to make the facility a reality, using a series of generous bequests.

The new location provides access for patients to early phase and high quality research into diseases of the heart and blood vessels. It allows protected space for teams from the hospital and the University of Leeds to conduct this important research.

Professor John Greenwood, the Director of the Cardiovascular Clinical Research Facility, said: “The opening completes the last piece of a jigsaw in terms of research facilities here in Leeds, allowing the city to compete on equal terms with the leading centres in the UK.

"It will allow us improve the patient experience, focus resources and provide a base to develop new clinical studies, allowing us to build research capacity and develop new partnerships with industry and the academic sector."

While high quality cardiovascular research has occurred for many years at Leeds Teaching Hospitals, this facility brings it together in a dedicated space for the first time. The centre is already operational, and is seeing up to 150 patients a month with 17 studies currently ongoing.

Patients from around the region being treated at Leeds General Infirmary are approached during clinic visits if the clinician feels they are suitable for a study - it is the up to the patient to choose if they would like to take part.

There is evidence to show that research active hospitals have better patient outcomes than those that do not participate in research. Research gives patients the chance to receive new drugs and undergo new procedures.

This Facility will also generate new links with commercial partners and industry, allowing novel treatments to be evaluated. Most importantly patients may be able to receive these treatments at an earlier phase in their development.